

**Marvel Biosciences** is a drug development company with focus on developing new and patent protected drugs using synthetic derivatives of known and approved drugs to target new diseases. MB-204, its lead asset, focuses on the treatment and management of Alzheimer Disease and Depression.

## Company Information

**Ticker:** MRVL  
**Exchange:** TSXV  
**Headquarter:** Calgary, AB  
**Shares Outstanding:** 39.8 million  
**Market Cap:** \$3.97 million  
**Insider Ownership:** 33.6%

## Management Team

**Chief Executive Officer: J. Roderick Matheson**

- 40 years of experience in capital market and investments formerly at CIBC and Canaccord
- Over \$1 billion in financing in public and private biotech companies

**Chief Science Officer: Dr. Mark Williams**

- 15 years experience in drug development
- Author of 12 patents, inventor of DM199 (in Phase 2 trials for kidney disease/stroke)

## Contact Information

**Marvel Biosciences Corp.**

Tel: 403-770-2469

Email: [info@marvelbiosciences.com](mailto:info@marvelbiosciences.com)

**Investor Relations**


Virtus Advisory Group

Tel: 416-646-6779

Email: [info@virtusadvisory.com](mailto:info@virtusadvisory.com)


## The Problem

### Dementia Incidence by Age



Source: 2022 Alzheimer's Association, Alzheimer's & Dementia Vol 18, Issue 4, April 2022, 645-668

### Shift in the Global Demographic



Source: United Nations, [http://esa.un.org/wpp/qa/population-pyramids/population-pyramids\\_absolute.htm](http://esa.un.org/wpp/qa/population-pyramids/population-pyramids_absolute.htm)

- **40%** of AD patients suffer from Depression
- AD Market to grow to **\$25 Billion** by 2029


## The Solution

**MB-204** is a synthetic derivative of Istradefylline, an off-patent FDA-approved Parkinson's Disease drug. MB-204 is designed to treat and manage depression and Alzheimer's Disease (AD) by targeting A2A receptors, known to be a credible target and clinical interest in treatment of AD and related disorders. MB-204 is expected to enter Phase 1 human trials in Q3 2023.

**MB-204** compared to Istradefylline is

- **longer lasting**
- **shows higher reduction in depression symptoms**
- **lowers anxiety symptoms**

## Comparable Companies in Similar Stages of Development (\$CAD)



## Why Invest?

- MB-204 – A potential solution to a growing Alzheimer's and Depression market
- Comparable companies valued at ~\$65M at a similar toxicology stage compared to Marvel Biosciences' (valued at \$5M)
- Entering human Phase 1 trials by Q3 2023 – Comparable valuations of >\$100M

**Marvel will be in a position to review opportunities with larger pharmaceutical companies before Phase 2**